

Access to Medicine Foundation: Closing the health equity gap

The global health challenge

Access to medicine should never depend on where a person lives. Yet for millions of people in low- and middle-income countries, life-saving medicines, vaccines, diagnostics and other essential health products remain out of reach.

As health systems around the world face growing challenges, including drug-resistant infections, rising rates of heart disease and cancer, and the threat of future pandemics, the need to close healthcare access gaps has never been more urgent.

Our approach


For more than 20 years, the Access to Medicine Foundation has served as an independent, non-profit catalyst for change, tracking, benchmarking and guiding the world's most influential pharmaceutical companies to expand access to essential healthcare products for the people who need them most, regardless of where they live.

The value we bring

Substantial public health benefits	Exceptional value for money
2.6M deaths averted & 808M patients reached by 2030	\$60 USD return per \$1 invested

Our proven model of change

The Access to Medicine Foundation drives change through a multi-faceted model that combines rigorous research, engagement with pharmaceutical and healthcare companies to identify opportunities to expand access, and the power of [institutional investors](#) and governments to drive change and [impact](#). By bringing together key stakeholders across health, the Foundation helps turn commitments into measurable action.



Improving access to sickle cell disease care

Millions of people living with sickle cell disease, particularly in low- and middle-income countries, continue to face significant barriers to diagnosis, treatment and ongoing care. Access to essential health products remains fragmented and, in many settings, dependent on donor-supported programmes. These gaps contribute to preventable illness, disability and early death, especially among children and young adults.

Together, we can transform sickle cell disease care for children in Africa



7.7 million people live with sickle cell disease worldwide.



515,000 babies are born with the disease every year.



Nearly 80% of the global burden is in Sub-Saharan Africa.



50-90% of affected children in Sub-Saharan Africa die before their fifth birthday **without intervention**.

Our action: The Access to Medicine Foundation aims to strengthen access to sickle cell disease care across Africa through a unified action plan. By aligning priorities, defining companies' roles across continuum of care, and supporting country-level guidelines, procurement policies and incentives, the initiative will create a shared roadmap for action. We will then engage companies to scale up action by tracking progress, identifying new opportunities, and promoting best practices to improve patient access. By expanding sustainable access to sickle cell disease care, people can survive, thrive, and build healthier futures for themselves, their families and their communities.

Invest in Access

We are seeking to raise €300,000 to launch our sickle cell disease initiative and accelerate access to care across Africa.

Your contribution will help scale our evidence-based research and change-making efforts to improve access to essential health products for people living with sickle cell disease. Together, we can help bring us closer to a future where they can survive, thrive and live healthier lives.

To learn how your support can improve access to essential health products for people living in LMICs, please contact:

Jayasree K. Iyer, CEO, Access to Medicine Foundation

Learn more: www.accesstomedicinefoundation.org